Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer

NCT06009848 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Cadonilimab

Sponsor

Tianjin Medical University Second Hospital